| dc.contributor.advisor | HADNING, INGENIDA | |
| dc.contributor.author | NEGERIANA, RIZKI PUTERI | |
| dc.date.accessioned | 2020-03-13T06:30:44Z | |
| dc.date.available | 2020-03-13T06:30:44Z | |
| dc.date.issued | 2019-07-19 | |
| dc.identifier.uri | http://repository.umy.ac.id/handle/123456789/32510 | |
| dc.description | Hipertensi disebut sebagai penyakit silent killer. Komplikasi yang
disebabkan oleh hipertensi seperti stroke, kebutaan, dan gagal ginjal. Indonesia
menempati peringkat kedua dengan penderita hipertensi terbanyak di kawasan
Asia Tenggara. Daerah Istimewa Yogyakarta (DIY) merupakan provinsi
tertinggi ketiga penderita hipertensi pada usia ≥ 18. Pengobatan penyakit
hipertensi dilakukan selama seumur hidup, dikarenakan tujuan dari pengobatan
hipertensi adalah untuk mengontrol tekanan darah pasien. Oleh sebab itu, beban
biaya yang harus dikeluarkan pasien cukup besar. Tujuan dari penelitian ini yaitu
mengetahui hasil studi Cost Effectiveness Analysis dari Amlodipin atau
Captopril pada penderita hipertensi primer rawat jalan di Puskesmas Seyegan.
Penelitian ini merupakan penelitian observasional non eksperimental
dengan desain studi cohort. Pengambilan data dilakukan secara retrospektif
dengan teknik pengambilan data Total Sampling, sehingga didapatkan sampel
sebanyak 111 rekam medis pasien. Analasis data menggunakan univariat yaitu
rata-rata biaya dan efektivitas, juga menggunakan analisis farmakoekonomi
berupa nilai ACER atau ICER. Uji statistik pada penelitian ini menggunakan uji
Mann-Whitney dan Independent Sample T test.
Hasil penelitian menunjukan rata-rata biaya terapi Amlodipin 5 mg sebesar
Rp22.000 dengan efektivitas 60%, Amlodipin 10 mg sebesar Rp47.150 dengan
efektivitas 43,75%, dan Captopril 25 mg sebesar Rp12.700 dengan efektivitas
50%. Hasil ACER Amlodipin 5 mg sebesar Rp367, Amlodipin 10 mg Rp1.078,
dan Captopril 25 mg sebesar Rp254. Dilakukan perhitungan ICER karena obat
alternatif (Captopril 25 mg) memiliki biaya dan efektifitas lebih rendah
dibandingkan dengan obat pembanding (Amlodipin 5 mg), diperoleh hasil ICER
sebesar Rp930. Pengobatan hipertensi primer pada Puskesmas Seyegan,
penggunaan antihipertensi Captoril 25 mg mutlak lebih cost effective daripada
antihipertensi Amlodipin 10 mg. Perhitungan ICER dilakukan pada Amlodipin
5 mg dengan Captopril 25 mg, diperoleh nilai ICER sebanyak Rp930 untuk
setiap peningkatan 1% efektivitas. | en_US |
| dc.description.abstract | Hypertension is called the silent killer disease. Complications caused by
hypertension such as stroke, blindness, and kidney failure. Indonesia ranks second
with the most hypertensive sufferers in the Southeast Asia region. Yogyakarta
Special Region (DIY) is the third highest province of hypertensive patients at the
age of ≥ 18. Treatment of hypertension is carried out for a lifetime, because the goal
of treating hypertension is to control the patient's blood pressure. Therefore, the
patient's burden must be quite large. The purpose of this study was to find out the
results of the Cost Effectiveness Analysis study of Amlodipine or Captopril in
outpatient primary hypertension patients at the Seyegan Health Center.
This study is a non-experimental observational study with a cohort study
design. Data retrieval was done retrospectively with the Total Sampling data
collection technique, so that a sample of 111 patient medical records was obtained.
Data analysis using univariate, namely the average cost and effectiveness, also uses
pharmacoeconomic analysis in the form of ACER or ICER values. The statistical
test in this study used the Mann-Whitney test and the Independent Sample T test.
The results showed that the average cost of Amlodipin 5 mg therapy was
IDR 22,000 with an effectiveness of 60%, Amlodipine 10 mg for IDR 47,150 with
the effectiveness of 43.75%, and Captopril 25 mg for IDR 12,700 with a
effectiveness of 50%. The results of ACER Amlodipine 5 mg were Rp. 367,
Amlodipine 10 mg Rp1,078, and Captopril 25 mg IDR 254. ICER calculations were
carried out because alternative drugs (Captopril 25 mg) had lower costs and
effectiveness compared to comparable drugs (Amlodipine 5 mg), ICER results were
obtained at Rp930. Treatment of primary hypertension at the Puskesmas Seyegan,
the use of antihypertensive Captoril 25 mg is absolutely more cost effective than
antihypertensive Amlodipine 10 mg. ICER calculations were carried out on
Amlodipine 5 mg with Captopril 25 mg, obtained ICER value of Rp930 for each
1% increase in effectiveness. | en_US |
| dc.publisher | FAKULTAS KEDOKTERAN DAN ILMU KESEHATAN UNIVERSITAS MUHAMMADIYAH YOGYAKARTA | en_US |
| dc.subject | captopril, amlodipine, cost effectiveness analysis, primary hypertension. | en_US |
| dc.title | COST EFFECTIVENESS ANALYSIS PENGGUNAAN CAPTOPRIL DAN AMLODIPIN PADA PASIEN HIPERTENSI PRIMER RAWAT JALAN DI PUSKESMAS SEYEGAN | en_US |
| dc.type | Thesis SKR FKIK 432 | en_US |
